Clinical Trials

Clinical Trial
  • Status: Not yet recruiting
  • Phase: Phase 1
  • Intervention Type: Drug
  • Participants: 18
  • Start Date: March 2021
Neoadjuvant Nivolumab Plus Ipilimumab for Newly Diagnosed Malignant Peripheral Nerve Sheath Tumor
Search for trials
Clinical Trial
  • Status: Recruiting
  • Phase: Phase 1
  • Intervention Type: Biological, Procedure, Radiation, Drug
  • Participants: 25
  • Start Date: October 14, 2020
A Phase I Study of Nivolumab and Intratumoral BO 112 for Resectable Soft Tissue Sarcoma
Clinical Trial
  • Status: Recruiting
  • Phase: Phase 2
  • Intervention Type: Biological, Drug, Procedure
  • Participants: 40
  • Start Date: August 19, 2020
A Pilot Study of Allogeneic Hematopoietic Stem Cell Transplantation for Pediatric and Adolescent-Young Adults Patients With High Risk Solid Tumors
Clinical Trial
  • Status: Recruiting
  • Phase: Phase 1
  • Intervention Type: Biological
  • Participants: 68
  • Start Date: July 13, 2020
Phase I Study of B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults
Clinical Trial
  • Status: Recruiting
  • Phase: Phase 2
  • Intervention Type: Drug
  • Participants: 70
  • Start Date: September 18, 2019
Larotrectinib (LOXO-101, NSC# 788607) for Previously Untreated TRK Fusion Pediatric Solid Tumors and TRK Fusion Relapsed Pediatric Acute Leukemias
Clinical Trial
  • Status: Recruiting
  • Phase: Phase 2
  • Intervention Type: Drug
  • Participants: 34
  • Start Date: September 5, 2019
Cetuximab, Irinotecan and Fluorouracile in fiRst-line Treatment of Immunologically-selected Advanced Colorectal Cancer Patients: the CIFRA Study
Clinical Trial
  • Status: Not yet recruiting
  • Phase: N/A
  • Intervention Type: Other
  • Participants: 500
  • Start Date: September 2019
Multimodal Immune Characterization of RAre Soft Tissue Sarcoma - MIRAS Project From SARRA (SARcome RAre) Project of the French Sarcoma Group
Clinical Trial
  • Status: Recruiting
  • Phase: Phase 1/Phase 2
  • Intervention Type: Drug
  • Participants: 100
  • Start Date: July 1, 2019
A Phase 1/2 Study of the Oral RET Inhibitor LOXO 292 in Pediatric Patients With Advanced RET-Altered Solid or Primary Central Nervous System Tumors
Showing 1-12 of 28